| BRAF Mutations in Hairy-Cell Leukemia E Tiacci, V Trifonov, G Schiavoni, A Holmes, W Kern, MP Martelli, ... New England Journal of Medicine 364 (24), 2305-2315, 2011 | 1204 | 2011 |
| Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage … A Gallamini, M Hutchings, L Rigacci, L Specht, F Merli, M Hansen, C Patti, ... Journal of clinical oncology 25 (24), 3746-3752, 2007 | 1026 | 2007 |
| Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma A Younes, LH Sehn, P Johnson, PL Zinzani, X Hong, J Zhu, C Patti, ... Journal of Clinical Oncology 37 (15), 1285-1295, 2019 | 505 | 2019 |
| Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi … A Gallamini, F Zaja, C Patti, A Billio, MR Specchia, A Tucci, A Levis, ... Blood, The Journal of the American Society of Hematology 110 (7), 2316-2323, 2007 | 392 | 2007 |
| Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis … M Ladetto, F De Marco, F Benedetti, U Vitolo, C Patti, A Rambaldi, ... Blood, The Journal of the American Society of Hematology 111 (8), 4004-4013, 2008 | 293 | 2008 |
| Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) AM Gianni, M Magni, M Martelli, M Di Nicola, C Carlo-Stella, S Pilotti, ... Blood 102 (2), 749-755, 2003 | 289 | 2003 |
| Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed … A Gallamini, C Tarella, S Viviani, A Rossi, C Patti, A Mulé, M Picardi, ... Journal of Clinical Oncology 36 (5), 454-462, 2018 | 191 | 2018 |
| Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses A Gallamini, C Patti, S Viviani, A Rossi, F Fiore, F Di Raimondo, ... British journal of haematology 152 (5), 551-560, 2011 | 179 | 2011 |
| Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in … C Tarella, R Passera, M Magni, F Benedetti, A Rossi, A Gueli, C Patti, ... Journal of Clinical Oncology 29 (7), 814-824, 2011 | 176 | 2011 |
| Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi C Visco, A Chiappella, L Nassi, C Patti, S Ferrero, D Barbero, ... The Lancet Haematology 4 (1), e15-e23, 2017 | 145 | 2017 |
| High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and … AJM Ferreri, G Donadoni, MG Cabras, C Patti, M Mian, R Zambello, ... Journal of Clinical Oncology 33 (33), 3903-3910, 2015 | 124 | 2015 |
| A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma F Morschhauser, P Feugier, IW Flinn, R Gasiorowski, R Greil, Á Illés, ... Blood, The Journal of the American Society of Hematology 137 (5), 600-609, 2021 | 109 | 2021 |
| Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma P Corradini, U Vitolo, A Rambaldi, R Miceli, F Patriarca, A Gallamini, ... Leukemia 28 (9), 1885-1891, 2014 | 107 | 2014 |
| Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple … C Tarella, M Zanni, M Di Nicola, C Patti, R Calvi, A Pescarollo, V Zoli, ... Leukemia 21 (8), 1802-1811, 2007 | 98 | 2007 |
| Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie … C Tarella, M Zanni, M Magni, F Benedetti, C Patti, T Barbui, A Pileri, ... Journal of Clinical Oncology 26 (19), 3166-3175, 2008 | 92 | 2008 |
| Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study A Andriani, A Zullo, F Di Raimondo, C Patti, L Tedeschi, U Recine, ... Alimentary pharmacology & therapeutics 23 (6), 721-726, 2006 | 91 | 2006 |
| Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas S Cortelazzo, C Tarella, AM Gianni, M Ladetto, AM Barbui, A Rossi, ... Journal of Clinical Oncology 34 (33), 4015-4022, 2016 | 86 | 2016 |
| Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. D Albano, C Patti, L La Grutta, F Agnello, E Grassedonio, A Mulè, ... European journal of radiology 85 (2), 313-318, 2016 | 77 | 2016 |
| Whole‐body MRI, FDG‐PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma D Albano, C Patti, R Lagalla, M Midiri, M Galia Journal of Magnetic Resonance Imaging 45 (4), 1082-1089, 2017 | 74 | 2017 |
| The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy A Rambaldi, C Boschini, G Gritti, F Delaini, E Oldani, A Rossi, AM Barbui, ... American journal of hematology 88 (12), 1062-1067, 2013 | 71 | 2013 |
